



Development of a Potent Antimicrobial Peptide With Photodynamic Activity

Di Zhang^{1†}, Jingyi Chen^{1†}, Qian Jing^{1†}, Zheng Chen¹, Azeem Ullah¹, Longguang Jiang¹, Ke Zheng¹, Cai Yuan^{2*} and Mingdong Huang^{1*}

¹College of Chemistry, Fuzhou University, Fuzhou, China, ²College of Biological Science and Engineering, Fuzhou University, Fuzhou, China

OPEN ACCESS

Edited by:

Jack Wong, Caritas Institute of Higher Education, China

Reviewed by:

Kaushiki Mazudar, Kelly Government Solutions, United States Angela Cunha, University of Aveiro, Portugal Grzegorz Szewczyk, Jagiellonian University, Poland

*Correspondence:

Cai Yuan cyuan@fzu.edu.cn Mingdong Huang HMD_lab@fzu.edu.cn

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology

Received: 31 October 2020 Accepted: 08 April 2021 Published: 01 June 2021

Citation:

Zhang D, Chen J, Jing Q, Chen Z, Ullah A, Jiang L, Zheng K, Yuan C and Huang M (2021) Development of a Potent Antimicrobial Peptide With Photodynamic Activity. Front. Microbiol. 12:624465. doi: 10.3389/fmicb.2021.624465 The emergence of antibiotic-resistant bacteria poses a serious challenge to medical practice worldwide. A small peptide with sequence RWRWRW was previously identified as a core antimicrobial peptide with limited antimicrobial spectrum to bacteria, especially Gram-positive bacteria. By conjugating this peptide and its analogs with lipophilic phthalocyanine (Pc), we identified a new antibiotic peptide [PcG₃K₅(RW)₃]. The peptide demonstrates increased antimicrobial effect to both Gram-positive *Staphylococcus aureus* and Gram-negative *Escherichia coli*. In addition, Pc also provides added and potent antimicrobial effect upon red light illumination. The inhibitory efficacy of PcG₃K₅(RW)₃ was increased by ~140-fold to nanomolar range upon illumination. Moreover, PcG₃K₅(RW)₃ was safe for mammalian cell and promoted wound healing in the mouse infection model. Our work provides a new direction to optimize antimicrobial peptides to enhance antimicrobial efficacy.

Keywords: antimicrobial peptide, Gram-negative bacteria, phthalocyanine, hydrophobicity, antibiotic resistance

INTRODUCTION

During the past few decades, antimicrobial resistance (AMR) of bacteria has become a worldwide threat to public health. The WHO has recently issued a priority list of pathogen strains that have acquired resistance to most, and in some cases to all, antibiotics at a global level and advocates urgent needs to develop treatment for these AMR strains for human health (Tacconelli et al., 2018). The list includes both Gram-negative and Gram-positive bacterial strains. Gram-negative bacteria, with an outer membrane to protect themselves from unwanted compounds, are difficult to inhibit by traditional antibiotics (Payne et al., 2007; Lewis, 2013). Daptomycin is a lipopeptide antibiotic approved by the US Food and Drug Administration (FDA) in 2003 to treat infection induced by Gram-positive bacteria (Sauermann et al., 2008). Daptomycin contains amphiphilic 13mer peptide and a decanoyl fatty acid tail. Darobactin is a recently reported peptide antibiotic (Imai et al., 2019) with low toxicity and strong potency against AMR Gram-negative pathogens. Broad-spectrum antibiotics with inhibitory activities to both Gram-positive strains have strong advantages and are much needed.

Antimicrobial peptides (AMPs) have multiple targets on pathogenic microbes, including the cytoplasmic membrane and cell division and synthesis of essential proteins (Okorochenkov et al., 2012). One drawback of AMPs is their limited antimicrobial spectrum, susceptibility toward proteolytic degradation, and moderate antimicrobial activity (Habets and Brockhurst, 2012;

1

Niu et al., 2013). In addition, the strategy for AMP optimization is generally not well defined, except the development of various formulation methods (Mahlapuu et al., 2016), including nanocarriers. Arginine- and tryptophan-rich peptides are a class of promising lead structures with inhibitory effect against Grampositive bacterial strains but less activity against Gram-negative bacteria (Strom et al., 2002, 2003; Choi and Moon, 2009; Dennison et al., 2009; Albada et al., 2012; Arias et al., 2014; Wenzel et al., 2014, 2016a,b). The presence of lipophilic groups in AMPs appears to be important for high potency, as demonstrated by two successful examples. Daptomycin is a 13mer lipopeptide antibiotic containing decanoyl fatty acid tail and was approved by the US FDA in 2003 to treat infections caused by Grampositive bacteria (Sauermann et al., 2008). Darobactin is a recently reported peptide antibiotic (Imai et al., 2019) with low toxicity and strong potency and contains three aromatic rings.

A hexapeptide RWRWRW was shown to be the shortest unit possessing effective antimicrobial efficacy (Strom et al., 2003; Liu et al., 2007; Albada et al., 2012; Wenzel et al., 2016a). The peptide showed a limited antimicrobial spectrum of only medium antimicrobial activity against Gram-positive bacteria but less activity against Gram-negative bacteria. The structure and functional studies on these arginine- and tryptophan-rich peptides clearly demonstrated the importance of strong lipophobicity (Liu et al., 2007; Albada et al., 2012; Wenzel et al., 2016a) for antimicrobial activity. For example, tyrosine was found to be less effective in providing bulk and lipophilicity than tryptophan (Strom et al., 2003). In this work, we incorporate a new lipophilic group, phthalocyanine (Pc), into the RWRWRW unit to synthesize a series of peptides and identify a potent AMP (Scheme 1). Pc not only provides hydrophobicity for bacterial membrane attachment but also becomes photocytotoxic to microbes when illuminated by red light at a specific wavelength [680 nm; Morley and Charlton, 1995; Gardberg et al., 2001; named antimicrobial photodynamic therapy (aPDT)]. No known bacterial resistance to aPDT has been reported (Chen et al., 2017; Wainwright et al., 2017). The peptide is shown to be safe to mammalian cells and has antimicrobial activity in a wound infection mouse model. Importantly, the peptide is active not only against Gram-positive Staphylococcus aureus but also against Gram-negative bacteria and even to multiresistant bacterial strains [methicillin-resistant S. aureus (MRSA)]. In addition, with the illumination of red light, the antimicrobial efficacy increased by ~140-fold against either Gram-positive or -negative bacterial strains (IC50s of 85 nM against S. aureus and 163 nM against Escherichia coli). We also demonstrated the antibacterial efficacy of the peptide in a mouse skin infection model. The strategy used here can be used to empower and expand the antimicrobial spectrum of other AMPs.

MATERIALS AND METHODS

Materials

The side chain-protected peptides $G_3(RW)_3,\ G_3(RW)_3K_5,$ and $G_3K_5(RW)_3$ on Wang resin were obtained commercially (GL





Biochem Ltd., Shanghai). Beta-carboxy phthalocyanine zinc was developed by us by a method previously reported (Chen et al., 2006). Beta-carboxy phthalocyanine (β -PcCOOH) was purified on a silica column with N,N-dimethylformamide (DMF):acetone (3:1) as the second band. All the chemical reagents were analytical grade and used without further purification. Distilled water was used throughout the experiments. *E. coli* (ATCC 8739), *S. aureus* (ATCC 6538), and MRSA (ATCC 33591) were acquired from ATCC. Bioluminescent strains of *E. coli* DH5 α were constructed by transformation of plasmid pAKlux2.1, which contained a complete bacterial luciferase operon as described (Ullah et al., 2018; Chen et al., 2019), and *S. aureus* Xen29 (NCTC8532) containing a stable copy of the modified Photorhabdus luminescens luxABCDE operon was purchased from Shanghai Biofeng Company.

Synthesis and Characterization

 β -PcCOOH was conjugated with side chain-protected G₃(RW)₃, $G_3(RW)_3K_5$, or $G_3K_5(RW)_3$ on Wang resin. In a typical conjugation reaction, β -carboxy phthalocyanine zinc (49.76 mg, 0.08 mmol) was dissolved in 2 ml DMF. Hexafluorophosphate benzotriazole tetramethyl uronium (HBTU; 61 mg, 0.16 mmol) and diisopropylethylamine (DIEA; 0.1 ml) were added to the solution and stirred for 30 min. The Wang resin with peptide G₃(RW)₃, $G_3(RW)_3K_5$, or $G_3K_5(RW)_3$ (200 mg, 0.08 mmol) was added into the solution, and the mixture was stirred for 24 h. After the reaction was completed, the filtered solid was washed three times by DMF and methanol until the filtrate became colorless. The residue was then treated with 95% trifluoroacetic acid (TFA) for 4 h at room temperature to remove the protecting groups and the Wang resin. The TFA-treated solution was filtered on a Buchner funnel, and the filtrate was concentrated with rotary evaporation, followed by the addition of cool anhydrous ethyl ether to obtain precipitate. The new synthetic compounds were further purified on a preparative highperformance liquid chromatography (HPLC; Dalian Elite Analytical Instruments Co. Ltd., Dalian, China) using a reverse phase column (Sino Chrom ODS-BP, 10 mm), eluted with a linear gradient of 50-100% in dimethyl sulfoxide (DMSO) in 0.01% TFA in a period of 30 min at a flow rate of 5 ml/ min. UV-Vis spectra and photo-degraded curve was measured by BioTek Synergy 4 multi-mode microplate reader in a 96-well plate at room temperature. The UV-Vis absorption spectrum of antimicrobial Pc-peptides (APPs) in DMSO was typical of Pc with the strongest absorption at 678 nm (extinction coefficient of 118,380 L·mol⁻¹·cm⁻¹). The synthetic AMPs were further characterized by high-resolution mass spectra.

Antimicrobial Activity Assays Using Bioluminescent Bacteria

Bioluminescent bacteria were grown in Luria-Bertani (LB) culture medium at 37°C under aerobic conditions overnight 8–12 diluted 100 times to 10⁶ colony-forming units (CFU)/ ml in phosphate buffered saline (PBS) before incubating with the peptides. The peptide or new compounds were first dissolved in PBST (PBS with 0.05% Tween 20) to prepare 1-mM stock

solutions, and the solutions were then further diluted up to 100 μ M with PBST. The bacterial suspensions were then incubated in 96-well plates with the compound peptides. The luminescence was monitored for 1 h to measure the bacterial viability. The percentage of survived bacteria was determined from the luminescence intensities of the treated group divided by the luminescence signal of the controls.

For photo-assisted antimicrobial activity measurements against bioluminescent bacteria, we used a procedure similar to as above, but with illumination using LM-LED light (680 nm) for 6 min (light dose of 12 J/cm², 33.33 mW/cm²) after 10 min incubation of the bacterial suspensions and the compound peptides.

Antimicrobial Activity Assays Using ATCC Standard Strains

E. coli (ATCC 8739), *S. aureus* (ATCC 6538), or MRSA (ATCC 33591) were grown in LB culture medium at 37°C under aerobic conditions overnight (8–12 h) before use.

Minimum inhibitory concentrations (MICs) were measured by the double dilution method. Inocula of bacteria were prepared by adjusting overnight cultures in LB medium. Aliquots of 100 μ l of the inocula were mixed with 900 μ l peptides of serial double dilutions in centrifuge tubes and then incubated with shaking at 37°C for 20 h without light. MICs were defined as the lowest concentrations of the peptides that completely inhibit the growth of bacteria (final concentration of 10⁶ CFU/ml). Bactericidal kinetics assay was also determined. Different final concentrations (0, 1/8-, 1/4-, 1/2-, 1-MIC) of the peptides were added to the bioluminescent *S. aureus* suspension (10³ CFU/ml). The bacteria were incubated at 37°C and 150 rpm. An aliquot of 100 μ l of the suspension was taken out to measure the absorption at 600 nm on microplate reader once an hour for up to 12 h.

Photo-assisted antimicrobial activity assays of the compound peptides against ATCC standard strains were carried out by colony counting method. The agar plates with only bacterial suspension were used as negative control. The peptide and bacterial suspension were incubated together in 96-well microplates first. Under the same conditions, for comparison, the other groups were set without light. After incubation for 40 min at room temperature, aliquots of 100 µl were taken out of the solutions and placed on agar plates at serial dilutions, then incubated at 37°C for 18-24 h. Numbers of colonies were counted, and the antimicrobial rate (R) was calculated: $R = (B-A)/B \times 100\%$. Here, A is the bacterial colony number on the agar plates containing various concentrations of the peptides, and B is the colony number for negative control. A similar procedure was carried out to study the effect of low dose of light on the activity of PcG₃K₅(RW)₃ against S. aureus (ATCC 6538) and E. coli (ATCC 8739), except the changing irradiate light doses (0, 0.15, 0.3, 0.45, and 0.6 J/cm²).

Reactive Oxygen Species Measurement

The reactive oxygen species (ROS) generated by Pc mainly includes singlet oxygen and may also contain hydroxyl radical

in some cases. In this study, the ROS generation of PcG₃K₅(RW)₃ was measured with a probe [2,7-dichlorofluorescein diacetate (DCFH-DA)]. In the presence of ROS, 2',7'-dichlorofluorescein diacetate (DCFH-DA) can be converted to 2,7-dichlorofluorescein (DCF, ex 400 nm, em 528 nm). 1,3-Dimethyl-2-thiourea (DMT) is a quencher of hydroxyl radical, while NaN₃ is a quencher for singlet oxygen. In a 96-well white plate, peptide PcG₃K₅(RW)₃ or G₃K₅(RW)₃ (for control) was added into the solution of DCFH-DA (100 μ M) with or without DMT (1 M) and/or NaN₃ (30 mM) to the final concentration of peptide at 10 μ M and the total volume of 200 μ l (using PBS as buffer). The solutions were illuminated using a planar LED light source for 5 min at intervals, and the emission intensity of DCF at 528 nm was measured every 30 s after illumination. The no-light radiation group was used as control.

Scanning Electron Microscope

The morphology changes of bacteria treated with $PcG_3K_5(RW)_3$ were observed using SEM. Untreated bacteria acted as the control. *E. coli* strains (ATCC 8739) were harvested by centrifuging at 6,000 rpm for 10 min and washed with sterile PBStwice. For the fixation, the bacteria were fixed with precooling 2.5% (v/v) glutaraldehyde in PBS overnight at 4°C. For dehydration, the bacteria were dehydrated by a graded series of ethanol (30, 50, 70, 90, and 100%) for about 10 min. The dehydrated *E. coli* solution was dropwise onto silicon wafer and dried at 37°C overnight. Then, prepared specimens were sprayed with gold before observation using SEM.

Bacterial Membrane Permeability Assay

Membrane permeability of bacteria was determined by the 8-aniline-1-naphthalene sulfonic acid (ANS) uptake assay. The bacteria (10^{8} CFU/ml) were washed with PBS and suspended (3,000-4,000 rpm) to OD₆₀₀ = 0.1-0.3. PcG₃K₅(RW)₃ (final concentration of 10 μ M) was added to bacterial suspension (*E. coli* ATCC 8739) before illumination (light dose of 12 J/ cm², 33.33 mW/cm²) was conducted. A group without light illumination was set up as control. The fluorescent hydrophobic probe ANS with a final concentration of 5.65 mM was added to bacterial suspension, and fluorescence intensity was recorded. The excitation and emission wavelengths of ANS were set at 380 and 520 nm, respectively.

In vivo Antimicrobial Test in Mammal Anti-infection Model

A localized infection mouse model was established to evaluate the antibacterial activity of $PcG_3K_5(RW)_3$ against *S. aureus in vivo* according to the procedure that we previously established (Zhang et al., 2018; Chen et al., 2019). Kunming mice (4-weekold, 25 ± 2 g, purchased from Shanghai SLAC Laboratory Animal Co. Ltd., Shanghai, China) were maintained and handled in accordance with the recommendations of the Institutional Animal Care And Use Committee (IACUC). Mice were divided into three groups: two groups were treated with $PcG_3K_5(RW)_3$ and *S. aureus*, with or without light, another group was treated with only *S. aureus*. Each group had six mice. All groups of mice were allowed free access to water and food throughout the experimental process. In each group, excisional wounds (10 mm × 10 mm) was made on the dorsal surface of the mouse by disinfected scissors to a depth of 2.0 mm. The bottom of the wound was panniculus carnosus with no visible bleeding. An aliquot (50 µl) of mid-log phase *S. aureus* (10⁸ CFU/ml) was then inoculated into each wound of mice. In the experimental group, 50 µl saline solution of PcG₃K₅(RW)₃ at final concentration of 20 µM (concentration of MIC) was added into the wound surface after inoculation with *S. aureus*. The area of the wounds and body weight of mice were measured each day.

In vivo Biosafety and Stability Measurement

In order to evaluate the biosafety of $PcG_3K_5(RW)_3$, we measured its cytotoxicity on human embryonic lung fibroblast cells. Aliquots (100 µl) of cells (~10⁵ per ml) were incubated in 96-well plates with $PcG_3K_5(RW)_3$ at various concentrations (0.8, 1.6, 3.1, 6.3, 12.5, 25, 50, and 100 µM) at 37°C for 24 h. The culture medium was used as control. The cells were washed with PBS, then were divided into two groups, and the light group was exposed to 12 J/cm² of 680 nm light illumination. After another 12-h incubation, the culture medium was refreshed and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added. After 4-h incubation at 37°C, the absorbance at 490 nm was measured on a multi-mode microplate reader (BioTek Synergy 4). The inhibition rate of cell growth was calculated by the following equation:

$$Cell viability (\%) = \begin{pmatrix} Mean \ absorbance \ value \ of \\ treatment \ group \\ Mean \ absorbance \ value \ of \\ control \end{pmatrix} \times 100\%$$

Meanwhile, an *in vitro* hemolysis assay was performed to evaluate hemoglobin (Hb) release in the plasma (as an indicator of red blood cell lysis) following peptide $PcG_3K_5(RW)_3$ exposure. Typically, 450 µl 0.9% NaCl, 450 µl 2% red blood cells, and 100 µl $PcG_3K_5(RW)_3$ (at final concentrations of 0.5, 5, 50, and 500 µM) were mixed together and incubated in a 37°C for 30 min. Positive control (containing 450 µl 2% red blood cell only) and negative control (containing 550 µl 0.9% NaCl and 450 µl 2% red blood cell) were designed as quality controls. Then, red blood cells were pelleted down by centrifuging the samples at 1,500 rpm for 10 min. The supernatant was aspirated, and the extent of hemolysis was quantified by determining the amounts of released Hb in the supernatant at 545 nm against Hb standard. Hemolysis rate Z can be calculated by the following equation:

$$Z(\%) = \left(\frac{Dt - Dnc}{Dpc - Dnc}\right) \times 100\%$$

Here, *Dt*, *Dnc*, and *Dpc* represent the absorption values at 545 nm of samples, the negative controls, and the positive controls.

In order to test the stability of $PcG_3K_5(RW)_3$ when exposed to some proteases in human, we incubated the saline solution of $PcG_3K_5(RW)_3$ (final concentration of 100 µM) with high concentration (200 nM) of trypsin and equal volume of saline solution for the control group. Then, all groups were incubated at 37°C for 30 min. Supernatant of centrifugation was measured in HPLC, and the procedure was the same as we mentioned above.

In vivo Biodistribution and Clearance Measurement

In order to find out metabolic characteristics of $PcG_3K_5(RW)_3$ *in vivo*, we evaluated the biodistribution and clearance of $PcG_3K_5(RW)_3$ in organs and blood of mice. Kunming mice were divided into eight groups (five mice per group), and the $PcG_3K_5(RW)_3$ (50 µM), RWRWRW (0.4 mg/kg of mouse body weight), or saline was injected through the tail vein. The mice were sacrificed at 2, 4, 8, 12, 24, 36, 48, and 72 h post-injection, and their primary organs (liver, kidneys, heart, spleen, lung, stomach, intestines) or muscles were collected postmortem. Meanwhile, their blood was collected through enucleation of eyeballs. These samples were then washed with saline and imaged on the three-dimension FMT 2500TM LX (PerkinElmer, Waltham, MA, United States) using the same acquisition settings as the *in vivo* imaging to quantitate the peptide average concentrations in the samples.

The blood of mice was diluted 10 times with DMF, immediately after collection, and then centrifuged to get supernatant for further determination. The supernatant was measured by fluorescence spectrophotometer F-4600 (HITACHI, Tokyo, Japan). The fluorescence intensity was recorded. The excitation and emission wavelengths were set at 610 and 680 nm. Then, the plasma concentrations of the PcG₃K₅(RW)₃ were determined using a concentration-fluorescence standard curve we made. The plasma half-life ($t_{1/2}$) can be calculated by the following formula:

$$t_{1/2} = \frac{0.693}{(-2.303k)}$$

Here, k represents the slope of fluorescence intensity-log (concentration) regression equation.

Statistical Analysis

Each test was repeated at least three times. The data were presented as the means \pm SD. Statistical analysis was performed using one-way analysis of variance. Multiple comparisons of the means were done by the least significant difference test. All computations were made by employing statistical software.

RESULTS AND DISCUSSION

New Antimicrobial Peptides: Design, Synthesis, and Characterization

Introduction of hydrophobic moieties, like acyl or aliphatic chains, is an optimization strategy for stronger antimicrobial efficacy and broader antimicrobial spectrum (Radzishevsky et al., 2005, 2007; Smith et al., 2018). Pc is a synthetic hydrophobic compound with aromatic ring size equivalent to four indole side chains of tryptophan. The use of Pc has an added feature: upon absorption of light at 680 nm (maximal absorption of the Pc), Pc will undergo inter-system crossing and react with molecular oxygen, generating ROS that eliminates pathogens nearby (Zhang et al., 2018; Chen et al., 2019).

Here, we design a series of AMPs with Pc linked to RWRWRW hexapeptidyl unit separated by a triglycine spacer (**Figure 1**). The carboxyl terminal of peptides was not amidated to promote aqueous solubility after conjugating hydrophobic Pc group. Pentalysine moiety (K_5) was also integrated into the peptide chain for two purposes: (1) enhance aqueous solubility and (2) increase antimicrobial efficacy to Gram-positive strains. Polylysine is an FDA-approved food preservative used in sushi, with a dose up to 50 mg/kg, and has a wide antimicrobial spectrum with good activity inhibiting Gram-negative bacteria. Here, the pentalysine was incorporated at two different orientations: either before or after RWRWRW unit. As controls, the peptides without the Pc group or pentalysine moiety (K_5) were also generated for comparison.

To synthesize these peptides, the side chain-protected peptides were commercially acquired, followed by their covalent conjugation at amino terminal to a mono-carboxy Pc (Chen et al., 2006, 2011; Supplementary Figure S1). The compounds were purified to highly homogeneous based on C18 reverse phase column on HPLC. The order of retention times of the compounds was consistent with the hydrophilicity and polarity predicted based on their molecular structures (Figure 2A). Compounds 4 and 5 are well soluble in DMSO and aqueous solution. By comparison, compound 3 shows poor solubility in water (Figure 2B). The soluble antimicrobial Pc-peptide (APP) compounds 4 and 5 were characterized by electrospray ionization (ESI)-mass spectrometry (MS; Supplementary Figure S2). All the synthetic antimicrobial Pc-peptides (APPs) showed strong absorptions at 680 nm in DMSO (Figure 2C), the typical feature of Pc (Chen et al., 2006).

Antimicrobial Activities of the Antimicrobial Pc-Peptides *in vitro*

To evaluate the antimicrobial activity of APPs, we used bioluminescent Gram-positive S. aureus and Gram-negative E. coli, where the bioluminescent intensity [relative luminescence units (RLUs)] was proportional to the number of live bacteria. The peptides at various concentrations were incubated with the strains, and the luminescence was monitored on a microplate reader to obtain the IC₅₀ of new peptides against these bacteria (Table 1). Compound 4 or 5 was shown to possess 2-4 times higher efficacy on both bacterial strains than compound 1 or 2 (Table 1), especially against Gram-negative E. coli, which was likely due to the extra hydrophobicity provided by the Pc group. Compound 3 $[PcG_3(RW)_3]$ exhibited moderate efficacy to bacteria compared to compound 4 or 5 but with poor aqueous solubility. Compound 4 [PcG₃K₅(RW)₃] turned out to be the most effective compound against either Gram-positive S. aureus or Gram-negative E. coli with IC508 of 12.4 and 23.9 µM, respectively. It is likely that both Pc moiety and tryptophan residue of compound 4 anchor directly into the phospholipid bilayer of bacterial membrane and further lead to cell death.

To further validate the antimicrobial efficacy, we measured MIC on two bacterial strains (*E. coli* ATCC 8739, *S. aureus* ATCC 6538) and the MRSA strain (**Table 2**). The results verified the conclusion obtained using bioluminescent bacteria. Compounds with Pc group (compounds 3, 4, and 5) exhibited much stronger inhibitory efficacies against either *E. coli* or *S. aureus* than the compounds of peptides. Furthermore, MRSA strain showed similar sensitivity to the peptides as the wild-type *S. aureus* strain. It should be mentioned that the antimicrobial efficacy data here are in the same range but slightly lower than those previously reported for RWRWRW-NH₂ (Strom et al., 2002, 2003; Liu et al., 2007; Albada et al., 2012).

This is likely due to the lack of C-terminal amidation of our peptides, which appears to be a key parameter for the efficacy.

In addition, the bactericidal kinetic curves (**Figure 3**) were recorded to test the continuous antimicrobial effect on *S. aureus* and *E. coli* bacterial strains in 12 h with varied concentrations (0-, 1/8-, 1/4-, 1/2-, 1-MIC) of compound **4**, which exhibited the strongest activity among all the APPs. The bacteria grew the fastest in the absence of compound **4** and reached the highest plateau among this series. The bacterial growth rate decreased in proportion to the increased concentrations of compound **4**. At the concentration of MIC, the bacterial proliferation completely stopped (**Figure 3**).





FIGURE 2 | Characterization of the antimicrobial Pc-peptides (APPs) and Pc-COOH. The APPs had high purity based on high-performance liquid chromatography (HPLC) profiles on C18 column (A) and different solubility in both dimethyl sulfoxide (DMSO) and water (B). All APPs exhibited a strong absorption band at 678 nm in DMSO (C).

TABLE 1 | Half-maximal inhibitory concentrations (IC $_{\rm 50}$ s) of antimicrobial peptides against bacteria.

TABLE 2 | Minimum inhibitory concentrations (MICs) of antimicrobial peptides against different types of bacterial strains.

Compd #, peptide sequence	IC₅₀ (μM) against		
	S. aureus	E. coli	
1, G ₃ K ₅ (RW) ₃	45.6 ± 2.9	61.8 ± 4.3	
2, G ₃ (RW) ₃ K ₅	68.0 ± 3.2	135 ± 25.3	
3, PcG ₃ (RW) ₃	34.0 ± 4.0	73.8 ± 1.7	
4, PcG ₃ K ₅ (RW) ₃	12.4 ± 0.9	23.9 ± 1.0	
5, PcG₃(RW)₃K₅	34.7 ± 3.1	51.2 ± 5.5	

Half-maximal inhibitory concentrations ($|C_{sc}s|$) of antimicrobial peptides against Gram-positive strain S. aureus or Gram-negative strain E. coli. Each experiment was performed in triplicate.

Photo-Assisted Toxicity of the Antimicrobial Pc-Peptides *in vitro*

The large aromatic ring Pc also serves as a photosensitizer, generating singlet oxygen when illuminated with a 680-nm light, leading to an additional level of toxicity to bacteria (Ali-Adib et al., 1998; Wrobel and Dudkowiak, 2006; Bian and Jiang, 2016). We used a LED light source that provides a stable and uniform light with the maximal intensity around 680 nm without heating the sample (**Figure 4A**). We measured the IC₅₀ of compounds **4** and **5** on bioluminescent bacteria at a light dose of 12 J/cm² (**Figure 4B**). The photo-assisted

Compd #, peptide	Molecular mass	MIC (µM) against		
sequence	111255	S. aureus	MRSA	E. coli
1, G ₃ K ₅ (RW) ₃	1,855.1	107.8	107.8	>215.6
2, G ₃ (RW) ₃ K ₅	1,855.1	107.8	107.8	>215.6
3, PcG ₃ (RW) ₃	1,676.7	12.0	24.0	48.0
4, PcG ₃ (RW) ₃ K ₅	2,488.2	8.0	16.1	16.1
5, PcG ₃ K ₅ (RW) ₃	2,488.2	16.1	16.1	16.1

Each experiment was performed in triplicate.

antimicrobial toxicity of this series of compounds had an overall trend similar to the toxicity without light illumination (**Tables 1** and **3**). Compound **4** was found to have a strong antimicrobial efficacy, with IC₅₀s of 85 and 163 nM toward *S. aureus* and *E. coli*, respectively. We also measured the photo-assisted antimicrobial efficacy by colony counting method using ATCC standard strains at a starting concentration of 10⁶ CFU/ml (**Figure 4C**). The results showed that compound **4** induced up to 5-log (i.e., 99.999%) reduction of *S. aureus* (including antibiotic-resistant strain MRSA) and 3-log (i.e., 99.9%) reduction of *E. coli* at a low concentration (2 μ M) with 6 min illumination (light dose of 12 J/cm², 33.33 mW/cm²; **Figure 4D**). We also



FIGURE 3 | Bactericidal kinetics of $PcG_3K_5(RW)_3$. The bacterial growth of *Escherichia coli* (A) and *Staphylococcus aureus* (B) were slowed down in the presence of different concentrations at the concentration of $PcG_3K_5(RW)_3$ at 1/8, 1/4, 1/2, 1-fold of minimum inhibitory concentration (MIC). Each experiment was performed in triplicate. *, **, and *** indicate significant differences (p < 0.05, p < 0.01, and p < 0.001) from the corresponding control group.



FIGURE 4 | The antimicrobial activity of $PcG_3K_5(RW)_3$ (4) in the presence of light. The efficacy was measured in 96-well microplates under illumination by LM-LED (**A**). $PcG_3K_5(RW)_3$ showed higher antimicrobial activity against both bioluminescent *S. aureus* and bioluminescent *E. coli* under illumination (light dose of 12 J/cm², 33.33 mW/cm²) at a low concentration (2 μ M) compared to $PcG_3(RW)_3K_5$ (**B**). $PcG_3K_5(RW)_3$ induced up to 5-log reduction of *S. aureus* and 3-log reduction of *E. coli* under illumination (light dose of 12 J/cm², 33.33 mW/cm²) at a low concentration (2 μ M), which were measured by colony counting method (**C**). This peptide also showed similar activity against multiple resistant strains [methicillin-resistant *S. aureus* (MRSA)] (**D**). The result of short illumination indicated that the high light dose was not essential to trigger bacterial cell death (**E**). Error bars indicated SD for three replications. * and # indicate significant differences to the controls of *S. aureus* (light dose = 0) and *E. coli* (light dose = 0), respectively (p < 0.05).

studied the effect of light dose for $PcG_3K_5(RW)_3$ and found even a low dose of light (36-s exposure or 0.60 J/cm²,

33.33 mW/cm²) led to the elimination of about 80% of *E. coli* or 95% of *S. aureus* at the concentration of 2 μ M (Figure 4E).

Action Mechanisms of PcG₃K₅(RW)₃

The classic antimicrobial mechanism of AMPs is through disruption of the membrane. We studied the changes of bacterial membrane permeability after treatments by ANS, a probe for membrane permeability (Joshi et al., 1988; Liu et al., 2018). Once the probe enters the bacterial phospholipid bilayer membrane, its fluorescence intensity will increase (Misra et al., 2015). This reflects the accumulation of the probe in the lipid bilayer presumably due to the damage of cell wall, allowing more probe penetrating through cell wall and entering bacterial membrane. We observed that our peptide greatly enhanced the ANS fluorescence intensity (Supplementary Figure S3), demonstrating the increased membrane permeability. We also used SEM to study the surface morphology of *E. coli* after incubation with PcG₃K₅(RW)₃ with or without illumination of 680 nm. The results showed

TABLE 3 | IC_{50} s of antimicrobial Pc-peptides upon illumination (12 J/cm², 33.33 mW/cm²).

Compd #, peptide sequence	IC₅₀ (μM) against		
	S. aureus	E. coli	
1, G₃K₅(RW)₃	44.640 ± 4.720	59.240 ± 1.970	
2, G₃(RW)₃K₅	71.580 ± 2.820	129.230 ± 30.340	
3, PcG₃(RW)₃	0.108 ± 0.029	0.252 ± 0.014	
4, PcG ₃ K ₅ (RW) ₃	0.085 ± 0.020	0.163 ± 0.018	
5, PcG₃(RW)₃K₅	0.225 ± 0.056	0.303 ± 0.036	

Half-maximal inhibitory concentrations (IC₅₀S) of antimicrobial peptides against Grampositive strain S. aureus or Gram-negative strain E. coli when exposed to LED light (25 mW) for 6 min. Antimicrobial activity of Pc-peptides was further enhanced. Each experiment was performed in triplicate. that *E. coli*, a bacterium in a rod-like shape with a smooth surface (**Figure 5A**), presents little changes upon illumination (**Figure 5B**), while $PcG_3K_5(RW)_3$ induced morphological damage to *E. coli* (**Figure 5C**), a bacterium that was typically in a rod-like shape with a smooth surface but became wrinkled and twisted in the presence of $PcG_3K_5(RW)_3$. The damage was further exacerbated with light illumination (**Figure 5D**), leading to the outflow of cellular contents and complete fragmentation of the bacterial envelop.

Next, we studied the generation of ROS produced by $PcG_3K_5(RW)_3$ with 5 min illumination of red light (**Supplementary Figure S4**; Wainwright et al., 2017; Zhang et al., 2017). We observed the steady increase of fluorescence signals of ROS probe DCFH-DA with time, indicating the production of ROS. Two types of ROS are typically produced by Pc under light illumination: either Type I (free radical) or Type II (singlet oxygen ${}^{1}O_2$), which can be quenched by either DMT or NaN₃, respectively. We observed that the fluorescence of PcG₃K₅(RW)₃ was quenched to varying degrees in the presence of DMT or NaN₃ and reached the lowest in the presence of both quenchers. This indicated that PcG₃K₅(RW)₃ generates both types of ROS upon illumination.

Antimicrobial Activity of PcG₃K₅(RW)₃ in vivo

S. aureus is one of the leading causes of wound infection in hospitals and in the community and causes skin or soft tissue infections, which retard wound healing and may further lead to serious complications. A localized anti-infection model was established to evaluate the antibacterial activity of $PcG_3K_5(RW)_3$ against *S. aureus in vivo* (**Figure 6A**). The wounds without



FIGURE 5 | SEM micrographs of *E. coli* after incubation with $PcG_3K_5(RW)_3$ (23.9 μ M, i.e., IC_{50} without light) followed with **(A)** or without light illumination (6 J/cm² 680 nm) **(B)**. *E. coli* group without incubation with $PcG_3K_5(RW)_3$ **(C)** and *E. coli* group with light exposure **(D)** were used as controls.



* indicated a significant difference ($\rho < 0.05$) from the corresponding control group.

antimicrobial compounds showed infection and ulceration at the 3rd day after surgery (**Figure 6B**). The infection recovered 1–2 days later, and an identifiable scab formed in the infected area. However, the infection did not appear in the groups treated with the local administration of $PcG_3K_5(RW)_3$. This treatment group showed clear healing on the next day after surgery, indicating rapid anti-infection effects of the compound $PcG_3K_5(RW)_3$ on traumatic wound (**Figure 6C**). The results showed that $PcG_3K_5(RW)_3$ promoted wound healing and prevented or alleviated the infection.

In another group, mice were treated with one-time 680-nm illumination (12.0 J/cm², 33.33 mW/cm²) after addition of $PcG_3K_5(RW)_3$ (**Supplementary Figure S5**). This group showed better wound recovery than the ones without illumination at the first 3 days after surgery. This verified enhanced of illumination on inhibitory efficacy *in vitro*. Although the light was not essential for $PcG_3K_5(RW)_3$ to promote wound healing in the mammalian infection model, illumination of low-dosage

light (below 12 J/cm², 33.33 mW/cm²) is still an additional method to enhance the efficacy in clinical treatment. Besides, treatment with $PcG_3K_5(RW)_3$ to traumatic wound did not significantly alter the weight gain of mice during the observation (**Figure 6D**), indicating a good biological compatibility of $PcG_3K_5(RW)_3$.

Biosafety and Stability of $PcG_{3}K_{5}(RW)_{3}$ in vivo

There are two active components of $PcG_3K_5(RW)_3$: Pc and synthetic peptide $G_3K_5(RW)_3$ moiety. Pc-type compounds appear to be safe, as they have been used in close association with human. Pc has been used as a color dye for outfits and underwear in fabric industry for decades. A Pc derivative (Photosense[®]) has been used as an antitumor drug for cancer treatment in Ukraine since 1990s. In China, a Pc-based compound (Photocyanine[®]) is currently in Phase II clinical trial for patients with esophagus cancer with a dose of



FIGURE 7 | Biosafety of $PcG_3K_5(RW)_3$ *in vivo* to human embryonic lung fibroblast (HELF) cells (A) with or without light illumination (12 J/cm², 33.33 mW/cm²) and to the red blood cells (B). Pure water was used as a control. Error bars indicated SD for three replications. * and ** indicated significant differences (p < 0.05 and p < 0.01, respectively) from the corresponding control group.

0.05–0.1 mg/kg (Shao et al., 2012). Its Phase I trial demonstrated no major adverse effect in human at a dose of 2 mg/kg. Pc green (CAS Reg. No. 1328-53-6) has been approved by the FDA to use in contact lens, surgical suture, and latex condom as a color additive.

Despite these apparent safety records of Pc, we still evaluated the biosafety of $PcG_3K_5(RW)_3$ experimentally. We first used the human embryonic lung fibroblast (HELF) cells and red blood cells of mice to evaluate biosafety in vitro. The cells were incubated with PcG₃K₅(RW)₃ for 24 h, and the viability was measured by MTT assay (Figure 7A). The result showed that over 90% of cells survived after incubation with the medium concentration (IC₅₀ concentration against S. aureus in the absence of light illumination) of PcG₃K₅(RW)₃. Under illumination of 12 J/cm², the peptide killed only 5% of HELF cells at the concentration of 0.8 µM while inhibiting more than 99.9% of S. aureus or 99% of E. coli, demonstrating low cytotoxicity to normal mammalian cells. In addition, PcG₃K₅(RW)₃ exhibited no cytotoxicity to red blood cells at concentrations of 50 µM (Figure 7B), while $IC_{50}s$ of peptide against bacterial strains are below 25 uM.

Biodistribution and clearance of $PcG_3K_5(RW)_3$ in organs/ tissues were also studied in mice. As shown in **Figure 8A**, $PcG_3K_5(RW)_3$ accumulated mainly in livers and kidneys but much less in other organs/tissues. The average concentrations of $PcG_3K_5(RW)_3$ in the livers and kidneys reached ~35 nM and ~12 nM at 2-4 h (**Figure 8B**) and reduced gradually with time. At 72 h post-injection, the peptide average concentrations in primary organs/tissues were reduced to low levels (2–3 nM in livers and kidneys and lower than 1 nM in other organs/tissues). The results showed that $PcG_3K_5(RW)_3$ are mainly accumulated in liver and lung and cleared out in 72 h. Monitoring the Pc fluorescence intensity of compound **4** in mouse blood circulation at different time points after intravenous injection showed the plasma half-life of compound **4** was 11.09 h (**Figure 8C**).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

MH designed the project. CY and MH led the project and finalized the manuscript. DZ and QJ carried out the experiments, analyzed the results, and wrote the draft. JC, ZC, AU, LJ, and KZ assisted in the experiments and result analysis. All authors contributed to the article and approved the submitted version.

FUNDING

Our research work is financially supported by grants from the National Key R&D Program of China (2017YFE0103200) and the National Natural Science Foundation of China (22077016, 31670739, and 82070142).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.624465/ full#supplementary-material



FIGURE 8 | Biodistribution and clearance of $PcG_3K_5(RW)_3$ in mice. (A) *Ex vivo* fluorescence images of resected organs and tissues from the mice at different time points after injection (2–24 h post-injection). (B) Concentration of $PcG_3K_5(RW)_3$ in various organs and tissues at different time points after injection. (C) The concentration of $PcG_3K_5(RW)_3$ in mouse blood at different time points after intravenous injection. Error bars indicated SD for three replications.

REFERENCES

- Albada, H. B., Chiriac, A. I., Wenzel, M., Penkova, M., Bandow, J. E., Sahl, H. G., et al. (2012). Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups. *Beilstein J. Org. Chem.* 8, 1753–1764. doi: 10.3762/bjoc.8.200
- Ali-Adib, Z., Clarkson, G. J., McKeown, N. B., Treacher, K. E., Gleeson, H. F., and Stennett, A. S. (1998). Molecular assemblies of novel amphiphilic phthalocyanines: an investigation irate the self-ordering properties of complex functional materials. J. Mater. Chem. 8, 2371–2378. doi: 10.1039/a805557b
- Arias, M., Nguyen, L. T., Kuczynski, A. M., Lejon, T., and Vogel, H. J. (2014). Position-dependent influence of the three TRP residues on the membrane activity of the antimicrobial peptide, tritrpticin. *Antibiotics* 3, 595–616. doi: 10.3390/antibiotics3040595
- Bian, Y. Z., and Jiang, J. Z. (2016). Recent advances in phthalocyanine-based functional molecular materials. *Struct. Bond.* 172, 159–199. doi: 10.1007/430_2015_194
- Chen, J. C., Chen, N. S., Huang, J. F., Wang, J. D., and Huang, M. D. (2006). Derivatizable phthalocyanine with single carboxyl group: synthesis and purification. *Inorg. Chem. Commun.* 9, 313–315. doi: 10.1016/j. inoche.2005.12.002
- Chen, J. C., Chen, Z., Zheng, Y. Q., Zhou, S. Y., Wang, J. D., Chen, N. S., et al. (2011). Substituted zinc phthalocyanine as an antimicrobial photosensitizer for periodontitis treatment. *J. Porphyrins Phthalocyanines* 15, 293–299. doi: 10.1142/S1088424611003276

- Chen, J. C., Wang, W. J., Hu, P., Wang, D., Lin, F., Xue, J. P., et al. (2017). Dual antimicrobial actions on modified fabric leads to inactivation of drugresistant bacteria. *Dyes Pigments* 140, 236–243. doi: 10.1016/j.dyepig.2017.01.032
- Chen, J. Y., Yang, L., Chen, J. C., Liu, W. Z., Zhang, D., Xu, P., et al. (2019). Composite of silver nanoparticles and photosensitizer leads to mutual enhancement of antimicrobial efficacy and promotes wound healing. *Chem. Eng. J.* 374, 1373–1381. doi: 10.1016/j.cej.2019.05.184
- Choi, J., and Moon, E. (2009). Identification of novel bioactive hexapeptides against phytopathogenic bacteria through rapid screening of a synthetic combinatorial library. J. Microbiol. Biotechnol. 19, 792–802. doi: 10.4014/ jmb.0809.497
- Dennison, S. R., Harris, F., Bhatt, T., Singh, J., and Phoenix, D. A. (2009). The effect of C-terminal amidation on the efficacy and selectivity of antimicrobial and anticancer peptides. *Mol. Cell. Biochem.* 332, 43–50. doi: 10.1007/s11010-009-0172-8
- Gardberg, A. S., Doan, P. E., Hoffman, B. M., and Ibers, J. A. (2001). Singly and doubly oxidized phthalocyanine (pc) rings: [cu(pc)(ReO4)] and [cu(pc) (ReO4)(2)]. *Angew. Chem.* 40, 244–246. doi: 10.1002/1521-3773(20010105) 40:1<244::AID-ANIE244>3.0.CO;2-G
- Habets, M. G. J. L., and Brockhurst, M. A. (2012). Therapeutic antimicrobial peptides may compromise natural immunity. *Biol. Lett.* 8, 416–418. doi: 10.1098/rsbl.2011.1203
- Imai, Y., Meyer, K. J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S., et al. (2019). A new antibiotic selectively kills gram-negative pathogens. *Nature* 576, 459–464. doi: 10.1038/s41586-019-1791-1

- Joshi, U. M., Kodavanti, P. R. S., Coudert, B., Dwyer, T. M., and Mehendale, H. M. (1988). Types of interaction of amphiphilic drugs with phospholipid-vesicles. *J. Pharmacol. Exp. Ther.* 246, 150–157.
- Lewis, K. (2013). Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–387. doi: 10.1038/nrd3975
- Liu, Z. G., Brady, A., Young, A., Rasimick, B., Chen, K., Zhou, C. H., et al. (2007). Length effects in antimicrobial peptides of the (RW)(n) series. *Antimicrob. Agents Chemother.* 51, 597–603. doi: 10.1128/AAC. 00828-06
- Liu, D. F., Li, L. S., Chen, J. C., Chen, Z., Jiang, L. G., Yuan, C., et al. (2018). Dissociation of zinc phthalocyanine aggregation on bacterial surface is key for photodynamic antimicrobial effect. *J. Porphyrins Phthalocyanines* 22, 925–934. doi: 10.1142/S1088424618500888
- Mahlapuu, M., Hakansson, J., Ringstad, L., and Bjorn, C. (2016). Antimicrobial peptides: an emerging category of therapeutic agents. *Front. Cell. Infect. Microbiol.* 6:194. doi: 10.3389/fcimb.2016.00194
- Misra, R., Morrison, K. D., Cho, H. J., and Khuu, T. (2015). Importance of real-time assays to distinguish multidrug efflux pump-inhibiting and outer membrane-destabilizing activities in *Escherichia coli. J. Bacteriol.* 197, 2479–2488. doi: 10.1128/JB.02456-14
- Morley, J. O., and Charlton, M. H. (1995). Theoretical investigation of the structure and spectra of zinc phthalocyanines. J. Phys. Chem. 99, 1928–1934. doi: 10.1021/j100007a023
- Niu, Y. H., Wu, H. F., Li, Y. Q., Hu, Y. G., Padhee, S., Li, Q., et al. (2013). AApeptides as a new class of antimicrobial agents. Org. Biomol. Chem. 11, 4283–4290. doi: 10.1039/c3ob40444g
- Okorochenkov, S. A., Zheltukhina, G. A., and Nebol'sin, V. E. (2012). Antimicrobial peptides: mode of action and perspectives of practical application. *Biomed. Khim.* 58, 131–143. doi: 10.18097/pbmc20125802131
- Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat. Rev. Drug Discov.* 6, 29–40. doi: 10.1038/nrd2201
- Radzishevsky, I. S., Rotem, S., Bourdetsky, D., Navon-Venezia, S., Carmeli, Y., and Mor, A. (2007). Improved antimicrobial peptides based on acyl-lysine oligomers. *Nat. Biotechnol.* 25, 657–659. doi: 10.1038/nbt1309
- Radzishevsky, I. S., Rotem, S., Zaknoon, F., Gaidukov, L., Dagan, A., and Mor, A. (2005). Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. *Antimicrob. Agents Chemother.* 49, 2412–2420. doi: 10.1128/AAC.49.6.2412-2420.2005
- Sauermann, R., Rothenburger, M., Graninger, W., and Joukhadar, C. (2008). Daptomycin: a review 4 years after first approval. *Pharmacology* 81, 79–91. doi: 10.1159/000109868
- Shao, J., Xue, J., Dai, Y., Liu, H., Chen, N., Jia, L., et al. (2012). Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser PHOTOCYANINE: ROS production, apoptosis, cell cycle arrest. *Eur. J. Cancer* 48, 2086–2096. doi: 10.1016/j.ejca.2011.10.013
- Smith, P. A., Koehler, M. F. T., Girgis, H. S., Yan, D. H., Chen, Y. S., Chen, Y., et al. (2018). Optimized arylomycins are a new class of gram-negative antibiotics. *Nature* 561, 189–194. doi: 10.1038/s41586-018-0483-6

- Strom, M. B., Haug, B. E., Skar, M. L., Stensen, W., Stiberg, T., and Svendsen, J. S. (2003). The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 46, 1567–1570. doi: 10.1021/jm0340039
- Strom, M. B., Rekdal, O., and Svendsen, J. S. (2002). Antimicrobial activity of short arginine- and tryptophan-rich peptides. J. Pept. Sci. 8, 431–437. doi: 10.1002/psc.398
- Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., et al. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* 18, 318–327. doi: 10.1016/S1473-3099(17)30753-3
- Ullah, A., Zhang, Y. X., Iqbal, Z., Zhang, Y. X., Wang, D., Chen, J. C., et al. (2018). Household light source for potent photodynamic antimicrobial effect and wound healing in an infective animal model. *Biomed. Opt. Express* 9, 1006–1019. doi: 10.1364/BOE.9.001006
- Wainwright, M., Maisch, T., Nonell, S., Plaetzer, K., Almeida, A., Tegos, G. P., et al. (2017). Photoantimicrobials-are we afraid of the light? *Lancet Infect. Dis.* 17, E49–E55. doi: 10.1016/S1473-3099(16)30268-7
- Wenzel, M., Chiriac, A. I., Otto, A., Zweytick, D., May, C., Schumacher, C., et al. (2014). Small cationic antimicrobial peptides delocalize peripheral membrane proteins. *Proc. Natl. Acad. Sci. U. S. A.* 111, E1409–E1418. doi: 10.1073/pnas.1319900111
- Wenzel, M., Prochnow, P., Mowbray, C., Vuong, C., Hoxtermann, S., Stepanek, J. J., et al. (2016a). Towards profiles of resistance development and toxicity for the small cationic hexapeptide RWRWRW-NH2. *Front. Cell Dev. Biol.* 4:86. doi: 10.3389/fcell.2016.00086
- Wenzel, M., Schriek, P., Prochnow, P., Albada, H. B., Metzler-Nolte, N., and Bandow, J. E. (2016b). Influence of lipidation on the mode of action of a small RW-rich antimicrobial peptide. *Biochim. Biophys. Acta Biomembr.* 1858, 1004–1011. doi: 10.1016/j.bbamem.2015.11.009
- Wrobel, D., and Dudkowiak, A. (2006). Porphyrins and phthalocyanines functional molecular materials for optoelectronics and medicine. *Mol. Cryst. Liq. Cryst.* 448, 15–38. doi: 10.1080/15421400500377354
- Zhang, Y. X., Huang, P., Wang, D., Chen, J. C., Liu, W. Z., Hu, P., et al. (2018). Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles. *Nanoscale* 10, 15485–15495. doi: 10.1039/C8NR01967C
- Zhang, Y. X., Zheng, K., Chen, Z., Chen, J. C., Hu, P., Cai, L. R., et al. (2017). Rapid killing of bacteria by a new type of photosensitizer. *Appl. Microbiol. Biotechnol.* 101, 4691–4700. doi: 10.1007/s00253-017-8133-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Chen, Jing, Chen, Ullah, Jiang, Zheng, Yuan and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.